Roche’s Alzheimer’s drug fails in long-awaited trial
Trials show small benefit, but without statistical validity Roche setback leaves Biogen and Eisai as leaders in the field It’s up to Roche’s CEO-designate to revive development fortunes Roche shares down 3.4%, its development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) drug candidate for Alzheimer’s disease has not been shown to slow …
Roche’s Alzheimer’s drug fails in long-awaited trial Read More »